NanoString Technologies

NanoString 1018
Cancer Research
Study Entire Pathways or Multiple Pathways in a Single Reaction
Leading cancer researchers worldwide are leveraging NanoString’s digital profiling technology to explore the frontiers of cancer biology. As the importance of studying the role of signaling pathways in cancer biology grows, many researchers are finding that the nCounter Analysis System is an indispensable tool for accelerating their research. With the capability to generate digital results for up to 800 targets in a single reaction, the nCounter system enables precise analysis of entire pathways (or multiple pathways) faster and with less bench time.
Chemistry Designed for Pathway-based Cancer Research
  • Highly multiplexed - 800 targets per reaction
  • No amplification - tolerant of FFPE and no bias
  • Precision - digital counting means unparalleled reproducibility
  • Simple and fast - easier, faster data production
CNV & Karyotyping PAM50-based Breast Cancer Test

NANOU 2110-150px
Introducing NanoString University (NanoU) an On-Demand Resource Portal
NanoU features course offerings ranging from self-guided videos as well as instructor led live & interactive courses.

Create your profile today for full access to all training material.
Register >

CNV & Karyotyping
nCounter CNV CodeSets provide superior accuracy and reproducibility for studies of all sizes. Achieve better results faster and with substantially less effort than with qPCR or arrays.
Product Highlights
  • Better, faster results with less effort than qPCR or arrays
  • Accurately target regions of interest
  • Lowest hands-on time of any platform on the market
  • Profile up to 800 regions of the human genome in a single reaction
PAM50-based Breast Cancer Test
NanoString Technologies obtained the CE Mark for its PAM50-based gene expression test for breast cancer, clearing the company to sell its test in the European Union and other countries recognizing the CE Mark.
NanoString’s test provides a subtype classification based on the fundamental biology of an individual’s breast tumor (referred to as intrinsic subtyping), as well as a prognostic score that predicts the probability of cancer recurrence over 10 years in post-menopausal women with hormone receptor-positive, early stage breast cancer (ESBC) who have been treated with hormonal therapy. Together with studies from the literature, this information has been shown to convey valuable information about a patient’s prognosis that can inform critical decisions about the patient’s course of therapy.